AZD5069

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary DiseaseSquamous Cell CarcinomaBronchiectasis

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

Xolair

Roche

Preclinical

252

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

303

AZD5069

AstraZeneca

Phase 2

24

Spiriva

Boehringer Ingelheim

Preclinical

85

Atrovent

Boehringer Ingelheim

Preclinical

56

Arcoxia

Novartis

Preclinical

—7

Formoterol Fumarate

AstraZeneca

Preclinical

88

Symbicort

AstraZeneca

Preclinical

69

Aciphex

Akero Therapeutics

Preclinical

210

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose2 trials

Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

Completed·AstraZeneca·Phase 1·NCT00953888·203 enrolled

Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

Completed·AstraZeneca·Phase 1·NCT01735240·15 enrolled

Asthma2 trials

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Completed·AstraZeneca·Phase 1·NCT01890148·13 enrolled

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.

Completed·AstraZeneca·Phase 2·NCT01704495·1,147 enrolled

Oral2 trials

Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069

Completed·AstraZeneca·Phase 1·NCT01332903·6 enrolled

This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose

Completed·AstraZeneca·Phase 1·NCT01083238·24 enrolled

Tics2 trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers

Completed·AstraZeneca·Phase 1·NCT01051505·8 enrolled

Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069

Completed·AstraZeneca·Phase 1·NCT01100047·63 enrolled

Squamous Cell Carcinoma1 trial

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Completed·AstraZeneca·Phase 1/2·NCT02499328·340 enrolled

4 more indications

Function1 trial

AZD5069 Neutrophil Function Study

Completed·AstraZeneca·Phase 1·NCT01480739·30 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed·AstraZeneca·Phase 2·NCT01233232·109 enrolled

Bronchiectasis1 trial

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Completed·AstraZeneca·Phase 2·NCT01255592·83 enrolled

Unspecified2 trials

Combination Study of AZD5069 and Enzalutamide.

Terminated·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT03177187·30 enrolled

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Completed·AstraZeneca·Phase 1·NCT01962935·84 enrolled

Details

Drug Info

Related News